BeOne Medicines Ltd. filed its Quarterly Report on Form 10-Q with the SEC for the quarterly period ended September 30, 2026, disclosing substantial revenue growth and a return to profitability across both the three- and nine-month periods.
Key Highlights
- Q3 2026 net product revenue: $1,855,057 thousand, up from $1,395,013 thousand in Q3 2025, according to the filing.
- Q3 2026 net income: $384,706 thousand, compared with $124,841 thousand in the prior-year quarter.
- Nine-month net income: $849,070 thousand for the nine months ended September 30, 2026, versus $220,431 thousand for the same period in 2025.
- Diluted EPS per ADS: $3.28 for Q3 2026 and $7.30 for the nine months ended September 30, 2026, as reported.
- Cash and cash equivalents: $5,781,128 thousand as of September 30, 2026, up from $4,547,530 thousand at December 31, 2025.
- Total assets: $9,875,925 thousand as of September 30, 2026, compared with $8,188,573 thousand at December 31, 2025.
- Shares outstanding: 1,483,318,035 ordinary shares as of September 30, 2026, per the balance sheet.
BeOne Medicines Q3 2026 Financial Results: Revenue and Income Trends
According to the filing, BeOne Medicines Ltd. (NASDAQ:ONC) reported total revenues of $1,889,815 thousand for the three months ended September 30, 2026, compared with $1,412,284 thousand for the same period in 2025. Net product revenue of $1,855,057 thousand in Q3 2026 drove the majority of that figure. For the nine months ended September 30, 2026, total revenues reached $5,108,324 thousand, up from $3,844,863 thousand in the nine months ended September 30, 2025.
The filing disclosed gross profit of $1,672,919 thousand for Q3 2026, rising from $1,215,774 thousand a year earlier. Total operating expenses for Q3 2026 were $1,254,244 thousand, comprising research and development costs of $660,784 thousand and selling, general and administrative expenses of $593,460 thousand. Income from operations for the quarter was $418,675 thousand, compared with $163,114 thousand in Q3 2025. For the nine-month period, income from operations was $993,624 thousand versus $262,101 thousand in the comparable 2025 period.
On the balance sheet, the company reported total shareholders' equity of $5,820,394 thousand as of September 30, 2026, up from $4,361,194 thousand at December 31, 2025. The accumulated deficit narrowed to $7,470,833 thousand from $8,319,903 thousand at year-end 2025. Short-term debt stood at $248,861 thousand and long-term debt at $825,220 thousand as of September 30, 2026, per the filing. As of October 30, 2026, the company disclosed 1,484,939,031 ordinary shares outstanding, including 766,039,443 shares held in the form of 58,926,111 American Depositary Shares, each representing 13 ordinary shares.
What Was Disclosed
BeOne Medicines Ltd. filed a Form 10-Q for the quarter ended September 30, 2026, reporting Q3 net income of $384,706 thousand, nine-month net income of $849,070 thousand, total assets of $9,875,925 thousand, and cash of $5,781,128 thousand.



Please wait processing your request...